Defining a therapeutic range for adalimumab serum concentrations in the management of pediatric noninfectious uveitis, a step towards personalized treatment

• Main Authors: Jo L. Dehoorne (Author), Helena Groth (Author), Emma Carlé (Author), Ilse De Schrijver (Author), Celine Sys (Author), Patricia Delbeke (Author), Elke O. Kreps (Author), Thomas Renson (Author), Carolien Bonroy (Author)
• Format: Book
• Published: BMC, 2023-12-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Background Adalimumab is currently considered the most efficacious anti-TNFα agent for childhood noninfectious uveitis (NIU). The objective of this study was to define a therapeutic range for adalimumab trough levels in the treatment of childhood NIU. Methods A retrospective, observational,...